Welcome to The MSI Consultancy News board. This section will be regularly updated to with news and information as well as as details of some of the on going and completed projects that we feel might be of particular interest to you.
Click the titles to read each of the news items.
![]() |
In an increasingly lean pharmaceutical industry maximising return on investment (ROI) is absolutely critical. However, being confident of the specific impact of your sales and marketing activities can be challenging...Contributor: Paul Stuart-Kregor (21-08-2008) |
![]() |
More than any other industry, pharmaceuticals cannot exist in a one-market ‘bubble’ - and this means that dealing with different cultures is inevitable...Contributor: Paul Stuart-Kregor (10-07-2008) |
![]() |
New ABPI code demands greater transparencyContributor: Paul Stuart-Kregor (10-07-2008) |
![]() |
The pharma industry has traditionally lagged behind other sectors when it comes to measuring the effectiveness of its marketing activity...Contributor: Jon Bircher (10-07-2008) |
![]() |
Dr Paul Stuart-Kregor argues that although global branding is a fact of life in the pharma industry...Contributor: Paul Stuart-Kregor (10-07-2008) |
![]() |
As a marketer in the international pharmaceutical world, it is very likely that the brand we are responsible for has a global presence...Contributor: Michael Craig (10-07-2008) |
![]() |
In this new series we take a snapshot look at some of the issues facing our Pharma colleagues within Europe...Contributor: Gerard Doherty (10-07-2008) |
![]() |
Is This the Beginning of the End?Contributor: Paul Stuart-Kregor (09-07-2008) |
![]() |
Would you envy someone who is dying from cancer? On the face of it, probably not. After all it is the ‘Big C’.Contributor: Paul Stuart-Kregor (09-05-2008) |
![]() |
Dr Richard Jones and Alex Blyth explain the meaning behind one of pharma marketing’s buzz phrases.Contributor: Richard Jones & Alex Blyth (09-05-2008) |
![]() |
Here we go again! Pharmaceutical brand marketers can be forgiven for feeling that yet again they are under attack, and the bad boys and girls of the marketing world.Contributor: Paul Stuart-Kregor (05-03-2008) |
![]() |
From the amount of lip service the Pharma industry pays to marketing effectiveness you might be excused for thinking it is already firmly entrenched in the industry...Contributor: Alex Blyth (29-02-2008) |
![]() |
Blogs have more to offer than just a home for pharma gossip says Dominic TyerContributor: Dominic Tyer & Paul Stuart Kregor (30-01-2008) |
![]() |
In this feature, we tackle the subject of the regional marketing team and look at a number of issues including, how can these regional marketing teams really add value...Contributor: Richard Jones (30-01-2008) |
![]() |
A great way of achieving growth in this era of squeezed pipelines and decreasing product differentials is to maximise the market for existing products.Contributor: Paul Stuart Kregor (30-01-2008) |
![]() |
Three years after the huge expansion of the EU, and with other countries such as Turkey champing at the bit to join the club, what is required to market successfully across the continent? Paul Stuart-Kregor asks whether a ‘European’ approach is really feContributor: Paul Stuart-Kregor (05-01-2008) |
![]() |
Considering the development needs of pharma marketers will help both the individuals and their employers, argues Gerard Doherty of the MSI ConsultancyContributor: Gerard Doherty (05-01-2008) |
![]() |
Concentrating solely on the prescriber and neglecting the patient can lead to a ‘leaky bucket’ post-launch, explains Dr Richard Jones.Contributor: Richard Jones (05-01-2008) |
![]() |
Dr Paul Stuart-Kregor argues that a period spent on the consultants’ side of the fence is a big plus point in a pharma marketing career.Contributor: Paul Stuart Kregor (18-09-2007) |
![]() |
In the first of a three-part series, Alex Blyth from The MSI Consultancy introduces a novel solution to the age-old problem of finding ways to deliver growth across a portfolio of in market brands.Contributor: Alex Blyth (18-09-2007) |
![]() |
Communicating with key people in a rapidly changing NHS requires looking at the bigger picture - and a better understanding of what is driving those changes, says Jon Bircher.Contributor: Jon Bircher (18-09-2007) |
![]() |
We all share a common commercial objective within pharmaceutical marketing - maximising peak sales for our brands.Contributor: Paul Stuart Kregor (09-07-2007) |
![]() |
Whatever product or brand is chosen for the purposes of this article, somewhere high on the list of its key features will be “Improves quality of life” or a similar phrase.Contributor: Chris Marks (09-07-2007) |
![]() |
The annual planning process, for all its focus on analysis, or template completion, can easily fall into the apparently comfortable tactic of merely updating the activity from last year’s plans.Contributor: Paul Stuart Kregor (09-07-2007) |
![]() |
Getting prescribers to use your product requires real insight. But that is a word which is much misused and often misunderstood, says Jon Bircher.Contributor: Jon Bircher (05-07-2007) |
![]() |
Too much strategic planning in the pharma industry is based on \'more of the same\'. But in a changing marketplace, what might at first seems like the safe option is anything but, says Dr Paul Stuart-Kregor.Contributor: Paul Stuart Kregor (29-05-2007) |
![]() |
One of the great truisms in life is that it is better to prevent than it is to treat. This is true for both our own approach to our health and also true for our customers in the way that they view many conditions.Contributor: Chris Marks (24-05-2007) |
![]() |
In recent years, the pharmaceutical industry has experienced a difficult period whereby productivity has not kept pace with increases in R&D investment. To counter this issue, an increasing number of companies have been focusing on drug repurposing.Contributor: Paul Stuart Kregor (24-05-2007) |
![]() |
When it comes to New Product Development, the difference between success and failure is well-resourced high performance teams, working with validated Target Product Profiles (TPP’s) argues John Lyttle.Contributor: John Lyttle (20-02-2007) |
View: Case studies | Articles | All downloads